IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in pa... von Starodub, Alexander, Gabrail, Nashat Y., Zhang, Ying, Torrejon Castro, Davis Y, Slavsky, Sibel, Singel, Stina Mui, Powderly, John D.

Volltext

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation von Starodub, Alexander, Powderly, John D., Kim, Sung-Bae, Davar, Diwakar, Hill, Andrew Graham, Yeku, Oladapo O., Gabrail, Nashat Y., Krapp, Christian, Pihl, Susanne, Zhang, Ying, Slavsky, Sibel, Torrejon Castro, Davis Y, Uyei, Anne, Singel, Stina Mui, Kwatra, Vineet

Volltext